*The following content is generated by AI and is for reference only.
<h3>Overview</h3>
<p><strong>Amenamevir</strong> (CAS: 1294657-88-1) is a novel oral antiviral agent developed for the treatment of herpes zoster. Its core synthesis involves specific heterocyclic coupling reactions to form the <strong>pyrimidine</strong> derivative structure with molecular formula C<sub>14</sub>H<sub>18</sub>N<sub>4</sub>O<sub>2</sub>.</p>
<h3>Application</h3>
<ul>
<li><strong>Virology Research:</strong> Used as a reference standard in developing new anti-herpes therapeutics.</li>
<li><strong>Clinical Trials:</strong> Serves as the active pharmaceutical ingredient (API) in Phase III studies for varicella-zoster virus inhibition.</li>
<li><strong>Pharmaceutical Manufacturing:</strong> Integrated into formulations targeting acute herpes zoster management in hospital settings.</li>
</ul>
<h3>Precautions</h3>
<p>Strictly contraindicated for patients with known hypersensitivity to amenamevir components. Requires storage under controlled conditions at 2°C–8°C to maintain chemical stability and potency during transport.</p>